What Tofago Treats: Main Uses and Benefits

Tofago is commonly used in contexts involving the acute management of vascular headaches and established migraine attacks. This therapeutic action is relevant for its role in the acute management of these disruptive episodes.

The medication is commonly used across conditions presenting with acute episodes and is particularly relevant for easing symptoms related to physical discomfort, especially the severe throbbing pain associated with migraine. In clinical scenarios, it is used for managing the symptoms of established attacks, including vascular headaches and acute migraine attacks.

Acute Relief for Severe Throbbing Pain

This medicine is commonly used to address groups of symptoms that may appear suddenly and interfere with daily comfort. It provides a migraine-specific approach and is relevant in areas where short-term symptom management is appropriate for migraine-specific symptoms. This relief generally contributes to improved comfort during periods of heightened symptoms and may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Acute Migraine Symptoms
Primary Therapeutic Goal	Assisting with the management of the established acute episode.
Symptom Focus	Severe throbbing pain associated with vascular headaches.
Use Context	Applied during phases when symptoms become more noticeable and supportive relief is needed.

Regulatory References

1. NIH MedlinePlus overview of Ergotamine and Caffeine

Tofago's eligibility is strictly defined by regulatory documents, restricting use primarily to adults for the acute management of established vascular headaches. The medicine is contraindicated and must not be used in a number of critical population groups.

Contraindications and Restrictions

Absolute contraindications include pregnancy (Category X) and individuals with severe pre-existing cardiovascular diseases, such as peripheral vascular disease, coronary heart disease, or uncontrolled hypertension. Use is also strictly prohibited in patients with severe hepatic or renal impairment, as well as those with sepsis or a history of fibrotic complications associated with ergot derivatives.

Furthermore, Tofago is contraindicated when taken concurrently with potent CYP 3A4 inhibitors (e.g., certain antibiotics). Use is not established in pediatric patients under 18 years of age, and it is not recommended for geriatric patients or for women who are breastfeeding. The drug is strictly limited to acute, non-chronic administration.

Tofago’s interaction profile is strictly defined by regulatory authorities and centers on two primary risks: metabolic interference and additive vasoconstrictive effects. The active ingredient, Ergotamine, is cleared primarily through the CYP3A4 enzyme system. Co-administration with strong CYP3A4 inhibitors is formally contraindicated as this pharmacokinetic interaction severely reduces clearance, resulting in elevated plasma concentrations of ergotamine. This increased exposure carries the risk of severe, prolonged vasospasm (ergotism).

Contraindicated Combinations (Regulatory Mandate)
Strong CYP3A4 Inhibitors: Macrolide antibiotics (e.g., Erythromycin, Clarithromycin); Protease inhibitors (e.g., Ritonavir, Indinavir); Azole Antifungals (e.g., Ketoconazole).
Vasoconstrictive Agents: Other ergot alkaloids; Triptans (5-HT1 agonists); other potent peripheral or central vasoconstrictors.

The medicine is also contraindicated with Triptans due to a pharmacodynamic interaction that increases the risk of additive vasospasm. To manage this risk, a mandatory 24-hour separation is required between the administration of Tofago and a Triptan. The consumption of Grapefruit Juice should be avoided due to its potential for CYP3A4 inhibition. Use is also restricted in patients with severe hepatic impairment, as their reduced ability to clear the medicine mimics a severe metabolic interaction.

Tofago functions by engaging two primary, complementary mechanisms—one targeting serotonin receptors to modulate activity within the neuro-vascular system, and another targeting adenosine receptors to influence vascular tone. This dual mechanism results in a focused adjustment of the physiological processes within the cranial vasculature.

---

Targeting Serotonin Receptors for Vasoconstriction

This mechanism is primarily driven by Ergotamine's non-selective agonism at 5-HT1B and 5-HT1D receptors. Activation of 5-HT1B causes the smooth muscles in dilated cranial vessels to contract, resulting in vasoconstriction. Simultaneously, activation of 5-HT1D on trigeminal nerve endings inhibits the release of potent vasodilators, such as CGRP, thereby reducing the signaling associated with neurogenic inflammation and influencing the level of mediator activity.

---

Caffeine's Role in Complementary Vascular Action

The secondary component, Caffeine, contributes through an independent mechanism: it is a non-selective antagonist of adenosine receptors (A1 and A2A). Since adenosine is a natural vasodilator, blocking its receptors promotes further vasoconstriction, complementing Ergotamine's vascular action. This synergistic effect promotes a more regulated state within the targeted pathways, resulting in the stabilization of cranial vascular responses.

How Tofago Is Used: Official Administration Guidelines

Administration of Tofago (Ergotamine/Caffeine) is strictly limited to the acute management of established vascular headaches and migraine attacks. The medicine is designed exclusively for intermittent, as-needed use and is explicitly **prohibited for chronic daily administration.

---

Administration Routes and Dosage Limits

The approved methods for taking this medication are Oral (tablet) and Rectal (suppository). Dosing must adhere to specific, labeled maximums for each episode and per week to control total drug exposure.

Instruction	Detail
Available Forms	Oral Tablet (1 mg Ergotamine / 100 mg Caffeine) or Rectal Suppository (2 mg Ergotamine / 100 mg Caffeine)
Initiation Timing	Taken at the first sign of an acute migraine attack
Maximum Dose per Attack	Limited to 6 tablets or 2 suppositories
Maximum Dose per 7 Days	Limited to 10 tablets or 5 suppositories

---

Procedural and Population Constraints

The standard protocol requires administration to be initiated early in the episode. For the tablet form, the initial dose is 2 tablets, with subsequent 1-tablet doses permitted every 30 minutes as needed, up to the attack limit. The suppository form's initial dose is 1 unit, with a single repeat dose permitted after 1 hour if required.

Labeling includes specific usage constraints. For instance, the consumption of grapefruit or grapefruit juice is prohibited during the use of this medicine. Safety and efficacy for pediatric patients have not been established, and the medication is not recommended for chronic preventative regimens. These constraints define the narrow, controlled context for Tofago's administration.

Research Evidence for Acute Management of Migraine Attacks

Research evidence, as documented in regulatory filings and scientific literature, indicates the drug combination was studied in the context of acute management of vascular headaches and acute migraine attacks. The evidence base includes older Randomized Controlled Trials (RCTs), which are considered a recognized type of study design, alongside systematic reviews that combine findings from multiple trials. These studies were evaluated in adults experiencing headaches classified as moderate or severe in intensity. The research examined patterns observed in these contexts, particularly focusing on outcomes related to physical discomfort and the disruption caused by the acute episodes.

The main outcomes measured in these studies included tracking patient-reported outcomes describing perceived discomfort, such as the level of headache response and achieving a pain-free status at specific intervals, commonly 2 hours after treatment. Researchers also monitored the sustainability of symptom patterns tracked, often tracking symptoms up to 24 to 48 hours to see whether symptoms recurred.

Consistency of Evidence and Study Limitations

While the evidence contributes to the broader evidence landscape for acute migraine management, certainty remains low when applying the findings universally. A key limitation is that the foundational studies often reflect older trial designs, and there is a documented lack of modern, high-quality placebo-controlled RCTs using current scientific standards. Comparative studies, where Tofago was evaluated in relation to newer drug classes (like triptans), have been conducted, and findings were mixed, suggesting a pattern of varied performance across different research settings.

Research Gaps and Remaining Uncertainties

Long-term effects are not fully established by the controlled clinical trials. The data are still emerging from large, non-interventional studies regarding the outcomes of continuous or very frequent use. Furthermore, data for certain groups remain insufficient, especially in pediatric or older adult populations. The primary research focus on episodic or acute changes means that long-term effects are not fully established and require continuous monitoring and further observational research.

Key Studies & References

1. Ergotamine/Caffeine - StatPearls - NCBI Bookshelf (Summary of indications, monitoring, and adverse effects)
2. Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology (Positions on ergotamines and MOH)

Common questions about Tofago (FAQ)

Q: What is the correct storage temperature for the tablets versus the suppositories?

According to official product information, the storage requirements vary significantly by formulation. Oral tablets are stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). Rectal suppositories require refrigeration at 2 C to 8 C (36 F to 46 F) and must not be frozen.

Q: What is Ergotism, and what are its symptoms?

Ergotism is a severe syndrome described in regulatory documents that results from intense narrowing of the arteries (vasoconstriction). Signs of Ergotism reported may include evidence of reduced blood flow to the limbs, such as experiencing cold extremities or muscle pains, or noting reduced pulses in the arms and legs. Other effects reported may include numbness or tingling in the fingers and toes.

Q: How long must I wait after taking Tofago before I can take a Triptan?

Regulatory warnings state that a mandatory 24-hour separation is required between the administration of Tofago and any Triptan medication. This waiting period helps to reduce the risk of additive vasospasm, which is the severe, combined narrowing of blood vessels caused by both drug classes.

Q: Can Tofago be crushed or split?

Official patient instructions for the rectal suppository form specifically advise users not to cut or break the suppository before use. The content does not explicitly state whether the oral tablet form can be crushed or split. Patients should use the medication exactly as provided by the manufacturer.

Q: What should I do if I miss a dose?

Since this is an acute, as-needed medication, there is no scheduled dosing regimen to miss. Regulatory guidance generally advises that the medicine can be taken when remembered for an acute attack, provided that patients adhere to the total attack limit and do not exceed the frequency of administration allowed by the product label.

Q: What are the common signs of an overdose on Tofago?

Signs of an overdose described in official product information can include problems with circulation, such as numbness, tingling, pain, and a bluish color in the fingers and toes. Other serious effects reported are severe sleepiness, seizures, pounding in the ears, and severe nausea and vomiting. Patients experiencing signs of overdose are advised to seek immediate emergency medical attention.

Q: Is Tofago addictive?

Regulatory information indicates that if this medicine is used for a prolonged period or too frequently, it may become habit-forming (leading to serious unwanted effects). The medication is classified for intermittent, as-needed use only, and its use is explicitly prohibited for chronic daily administration.

Q: What should I do with expired suppositories or tablets?

Official guidance states that the medication should not be flushed down a toilet or poured down a drain unless specifically instructed by a regulatory authority. Expired or unused Tofago should be disposed of in accordance with the official guidance, such as a local drug take-back program.

How to Store and Dispose of Tofago

Storage conditions for Tofago (Ergotamine Tartrate and Caffeine) vary strictly by formulation.

---

Storage Requirements

Formulation	Required Temperature	Protection from
Oral Tablets	Controlled Room Temperature: 20°C to 25°C (68°F to 77°F)	Light and excess moisture
Rectal Suppositories	Refrigeration Required: 2°C to 8°C (36°F to 46°F)	Freezing and moisture

Tablets must be dispensed in a tight, light-resistant container. Suppositories must be stored in their original sealed foil. If a suppository softens due to heat, it must be chilled in ice-cold water to solidify it before use.

---

Child Safety and Disposal

Both forms must be kept out of the sight and reach of children.

Expired or unused Tofago should be disposed of in accordance with official guidance. The medication must not be flushed down a toilet or poured down a drain unless specifically instructed to do so by a regulatory authority.